- Home
- SMSI vs ENLV Comparison
SMSI vs ENLV Comparison
Compare SMSI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- ENLV
- Stock Information
- Founded
- SMSI 1982
- ENLV 2005
- Country
- SMSI United States
- ENLV Israel
- Employees
- SMSI N/A
- ENLV N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- SMSI Technology
- ENLV Health Care
- Exchange
- SMSI Nasdaq
- ENLV Nasdaq
- Market Cap
- SMSI 24.7M
- ENLV 20.7M
- IPO Year
- SMSI 1995
- ENLV 1995
- Fundamental
- Price
- SMSI $0.76
- ENLV $1.01
- Analyst Decision
- SMSI Strong Buy
- ENLV Strong Buy
- Analyst Count
- SMSI 1
- ENLV 2
- Target Price
- SMSI $5.00
- ENLV $10.00
- AVG Volume (30 Days)
- SMSI 301.5K
- ENLV 146.1K
- Earning Date
- SMSI 05-07-2025
- ENLV 04-11-2025
- Dividend Yield
- SMSI N/A
- ENLV N/A
- EPS Growth
- SMSI N/A
- ENLV N/A
- EPS
- SMSI N/A
- ENLV N/A
- Revenue
- SMSI $20,555,000.00
- ENLV N/A
- Revenue This Year
- SMSI $36.40
- ENLV N/A
- Revenue Next Year
- SMSI $46.07
- ENLV N/A
- P/E Ratio
- SMSI N/A
- ENLV N/A
- Revenue Growth
- SMSI N/A
- ENLV N/A
- 52 Week Low
- SMSI $0.52
- ENLV $0.81
- 52 Week High
- SMSI $3.21
- ENLV $4.59
- Technical
- Relative Strength Index (RSI)
- SMSI 34.47
- ENLV 44.89
- Support Level
- SMSI $0.75
- ENLV $0.92
- Resistance Level
- SMSI $0.89
- ENLV $1.13
- Average True Range (ATR)
- SMSI 0.07
- ENLV 0.10
- MACD
- SMSI 0.01
- ENLV -0.01
- Stochastic Oscillator
- SMSI 28.33
- ENLV 24.32
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.